急性冠脉综合征患者PCI术后药物治疗管理模式的建立
|
摘要
目的建立急性冠脉综合征患者PCI术后药物治疗管理模式。方法参考国外药物治疗管理模式要点指南,结合医院现状,探索开展急性冠脉综合征患者PCI术后的药物治疗管理。结果建立急性冠脉综合征患者PCI术后药物治疗管理机制,成立药物治疗管理药师团队,制定随访规章制度及标准流程。结论开展急性冠脉综合征患者PCI术后的药物治疗管理有利于实现药物最大疗效,体现医疗服务内涵。
OBJECTIVE To establish a model of medication therapy management(MTM) for acute coronary syndrome(ACS) patients after percutaneous coronary intervention(PCI). METHODS Reference to the foreign MTM guide, combined with the status of the hospital, explored the implementation of MTM for ACS patients after PCI. RESULTS Established a mechanism of MTM for ACS patients after PCI, set up a MTM pharmacist team and developed follow-up rules, regulations and standard processes. CONCLUSION Management of MTM for ACS patients after PCI is conducive to achieve maximum medicine efficacy and reflect the connotation of medical services.
OBJECTIVE To establish a model of medication therapy management(MTM) for acute coronary syndrome(ACS) patients after percutaneous coronary intervention(PCI). METHODS Reference to the foreign MTM guide, combined with the status of the hospital, explored the implementation of MTM for ACS patients after PCI. RESULTS Established a mechanism of MTM for ACS patients after PCI, set up a MTM pharmacist team and developed follow-up rules, regulations and standard processes. CONCLUSION Management of MTM for ACS patients after PCI is conducive to achieve maximum medicine efficacy and reflect the connotation of medical services.
引文
[1]PELLEGRINO A N,MARTIN M T,TILTON J J,et al.Medication therapy management services:definitions and outcomes[J].Drugs.2009,69(4):393-406.
[2]National Association of Chain Drug Stores.Medication therapy management in pharmacy practice:core elements of an MTM service model,version 2.0[EB/OL].http://www.nacds.org/userassets/pdfs/MTM/Final MTMService Model_WEB.pdf.2008-12-30.2011-05-10.
[3]BARNETT M J,FRANK J,WEHRING H,et al.Analysis of pharmacist-provided medication therapy management(MTM)services in community pharmacies over 7 years.[J].J Manag Care Pharm,2009,15(1):18-31.
[4]RAMALHO DE OLIVEIRA D,BRUMMEL A R,MILLER DB.Medication therapy management:10 years of experience in a large integrated health care system[J].J Manag Care Pharm,2010,16(3):185-195.
[5]WU D,GE W H,YU F.Overview and connotation of the Amercian community medication therapy management[J].Chin Gen Prac(中国全科医学),2010,13(6):1773-1775.
[6]MA Y P.Development of the medication therapy management services and pharmacist’s service model in USA[J].China Pharm(中国药房),2012,23(9):854-856.
[7]余自成,刘皋林.药物治疗管理服务:药学监护实践中新的机遇[J].中国临床药学杂志,2015,24(5):313-317.
[8]JING L M,LOU S Y,REN S M,et al.Effect of intensive follow-up management after percutaneous coronary intervention in patients with coronary heart disease[J].Chin JEvid Based Cardiovasc Med(中国循证心血管医学杂志),2014,7(6):738-740.
[9]ZHOU J,CHEN Y F,ZHONG X L,et al.Effect of a strengthened education program on patient after percutaneous coronary intervention in hospital by clinical pharmacist[J].Pharm Today(今日药学),2016,26(9):663-665.
[10]王翠捷,廖国杭,罗振,等.临床药师参与社区慢性病管理对2型糖尿病患者用药依从性的影响[J].中国药物经济学.2017,12(4):153-155.
[11]AVEZUM A,MAKDISSE M,SPENCER F,et al.Impact of age on management and outcome of acute coronary syndrome:observations from the Global Registry of Acute Coronary Events(GRACE).[J].Am Heart J,2005,149(1):67-73.
[12]中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中国医学前沿杂志(电子版),2012,4(12):50-59.
[13]TANEJA A K,COLLINSON J,FLATHER M D,et al.Mortality following non-ST elevation acute coronary syndrome:4 years follow-up of the PRAIS UK Registry(Prospective Registry of Acute Ischaemic Syndromes in the UK)[J].Eur Heart J,2004,25(22):2013-2018.
[14]SHEN J,LUO S X,YANG Y P.Prevalence on secondary prevention and risk factors control for coronary heart disease[J].Chin J Mult Organ Dis Eld(中华老年多器官疾病杂志),2013,12(3):180-183.
[15]MAO S F,ZHAO S Y,ZHANG H H,et al.Study on medication adherence,self-management status and its influenc-ing factors after percutaneous coronary intervention[J].China Mod Doctor(中国现代医师),2014,52(31):124-128.
[2]National Association of Chain Drug Stores.Medication therapy management in pharmacy practice:core elements of an MTM service model,version 2.0[EB/OL].http://www.nacds.org/userassets/pdfs/MTM/Final MTMService Model_WEB.pdf.2008-12-30.2011-05-10.
[3]BARNETT M J,FRANK J,WEHRING H,et al.Analysis of pharmacist-provided medication therapy management(MTM)services in community pharmacies over 7 years.[J].J Manag Care Pharm,2009,15(1):18-31.
[4]RAMALHO DE OLIVEIRA D,BRUMMEL A R,MILLER DB.Medication therapy management:10 years of experience in a large integrated health care system[J].J Manag Care Pharm,2010,16(3):185-195.
[5]WU D,GE W H,YU F.Overview and connotation of the Amercian community medication therapy management[J].Chin Gen Prac(中国全科医学),2010,13(6):1773-1775.
[6]MA Y P.Development of the medication therapy management services and pharmacist’s service model in USA[J].China Pharm(中国药房),2012,23(9):854-856.
[7]余自成,刘皋林.药物治疗管理服务:药学监护实践中新的机遇[J].中国临床药学杂志,2015,24(5):313-317.
[8]JING L M,LOU S Y,REN S M,et al.Effect of intensive follow-up management after percutaneous coronary intervention in patients with coronary heart disease[J].Chin JEvid Based Cardiovasc Med(中国循证心血管医学杂志),2014,7(6):738-740.
[9]ZHOU J,CHEN Y F,ZHONG X L,et al.Effect of a strengthened education program on patient after percutaneous coronary intervention in hospital by clinical pharmacist[J].Pharm Today(今日药学),2016,26(9):663-665.
[10]王翠捷,廖国杭,罗振,等.临床药师参与社区慢性病管理对2型糖尿病患者用药依从性的影响[J].中国药物经济学.2017,12(4):153-155.
[11]AVEZUM A,MAKDISSE M,SPENCER F,et al.Impact of age on management and outcome of acute coronary syndrome:observations from the Global Registry of Acute Coronary Events(GRACE).[J].Am Heart J,2005,149(1):67-73.
[12]中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南2012(简本)[J].中国医学前沿杂志(电子版),2012,4(12):50-59.
[13]TANEJA A K,COLLINSON J,FLATHER M D,et al.Mortality following non-ST elevation acute coronary syndrome:4 years follow-up of the PRAIS UK Registry(Prospective Registry of Acute Ischaemic Syndromes in the UK)[J].Eur Heart J,2004,25(22):2013-2018.
[14]SHEN J,LUO S X,YANG Y P.Prevalence on secondary prevention and risk factors control for coronary heart disease[J].Chin J Mult Organ Dis Eld(中华老年多器官疾病杂志),2013,12(3):180-183.
[15]MAO S F,ZHAO S Y,ZHANG H H,et al.Study on medication adherence,self-management status and its influenc-ing factors after percutaneous coronary intervention[J].China Mod Doctor(中国现代医师),2014,52(31):124-128.